United States

Drug Pricing

Evidence to support 'breakthrough' drugs often very limited: study

(Reuters Health) - The 46 medicines given approval through 2017 as part of the U.S. Food and Drug Administration's Breakthrough Therapy program have often been sent to patients without a large double-blind study, direct measurement of benefit, or comparison with a placebo or existing treatment, according to a new analysis by researchers at Yale University and the Yale School of Medicine.

Published on Oct 23, 2015

This clip features Professor Meredith Rosenthal, Dr. Aaron Kesselheim and Dr. Steven Pearson, who spoke during Drug Pricing: Public Health Implications on Friday, October 23, 2015. The event was presented in collaboration with Reuters and in association with Harvard Health Publications.

More headlines

Pfizer separates consumer health unit in business rejig

Pfizer Inc announced plans on Wednesday to reorganize into three units, separating its consumer healthcare business that the U.S. drugmaker has been trying to sell since last year. | Video

Jul 11 2018

Trump told Pfizer CEO price hikes hurt his drug plan: source

NEW YORK/WASHINGTON U.S. President Donald Trump called Pfizer Chief Executive Ian Read on Tuesday to say the company's July 1 price hikes had complicated the administration's drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.

Jul 11 2018

Pfizer delays drug price hikes after talking with Trump

WASHINGTON/NEW YORK Pfizer Inc said on Tuesday it was deferring drug price increases for no more than six months after the company's chief executive officer had an extensive conversation with U.S. President Donald Trump.

Jul 10 2018

Trump slams Pfizer after July 1 drug price hikes

NEW YORK/WASHINGTON U.S. President Donald Trump on Monday took aim at Pfizer Inc and other U.S. drugmakers after they raised prices on some of their medicines on July 1, saying his administration would act in response.

Jul 09 2018

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

Jul 06 2018

Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic

NEW YORK In the escalating battle over U.S. prescription drug prices, major pharmaceutical companies are scrambling to limit the economic damage from a new U.S. insurer tactic that coaxes patients away from expensive drugs.

Jul 05 2018

Novartis hands investors Alcon spin-off, $5 billion share buyback

ZURICH Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.

Jun 29 2018

Amazon to buy PillPack in potentially disruptive drug retail push

Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the world's biggest online retailer in direct competition with drugstore chains, drug distributors and pharmacy benefit managers. | Video

Jun 28 2018

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

Jun 26 2018

Reuters Collaborations with The Forum at Harvard T.H. Chan School of Public Health


Health News


Bill Gates backs $30 million push for early Alzheimer's diagnostics

CHICAGO Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder on Tuesday said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer's disease.


China heart drug sold globally may have had impurity since 2012

LONDON A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012, European regulators said on Tuesday.


Judge rules for Trump administration in suit over family-planning program shift

A federal judge ruled on Monday against birth control organizations that sought to block the Trump administration from shifting a federal family-planning grant program toward prioritizing groups that are faith-based and counsel abstinence.

Teen suicide risk may be lower with intense team-based therapy

(Reuters Health) - Adolescents who have harmed themselves or tried to commit suicide may be less likely to do it again when they participate in an intense therapy program focused on both individual and family treatment, a U.S. study suggests.


Roche touts new flu drug as Tamiflu suffers generics hit

ZURICH Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications.